Literature DB >> 21851189

Clinical characteristics of children receiving antipsychotic medication.

Robert L Findling1, Sarah McCue Horwitz, Boris Birmaher, Robert A Kowatch, Mary A Fristad, Eric A Youngstrom, Thomas W Frazier, David Axelson, Neal Ryan, Christine A Demeter, Judith Depew, Benjamin Fields, Mary Kay Gill, Elizabeth A Deyling, Brieana M Rowles, L Eugene Arnold.   

Abstract

This study explored the demographic and diagnostic features of children who were currently receiving antipsychotics compared to children who were receiving other psychotropics in a cohort of children with and without elevated symptoms of mania (ESM). Participants were recruited from 10 child outpatient mental health clinics associated with four universities. Guardians with children between 6-12 years who presented for new clinical evaluations completed the Parent General Behavior Inventory-10 Item Mania Scale (PGBI-10M). All children who scored ≥12 on the PGBI-10M and a select demographically matched comparison group of patients who scored ≤11 were invited to participate. Children were divided into two groups: those receiving at least one antipsychotic medication and those receiving other psychotropic medications. The groups were compared on demographics, diagnoses, psychiatric symptoms, functioning, and past hospitalizations. Of the 707 children enrolled in the Longitudinal Assessment of Manic Symptoms (LAMS) study, 443 (63%) were prescribed psychotropic medication at baseline: 157 (35%) were receiving an antipsychotic and 286 (65%) were prescribed other agents. Multivariate results indicated that being prescribed antipsychotics was related to being white, previous hospitalization, having a psychotic or bipolar 1 disorder and the site where the child was receiving services (p<0.001). In this sample, it is relatively common for a child to be prescribed an antipsychotic medication. However, the only diagnoses associated with a greater likelihood of being treated with an antipsychotic were psychotic disorders or unmodified DSM-IV bipolar 1 disorder.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21851189      PMCID: PMC3157745          DOI: 10.1089/cap.2010.0138

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  28 in total

1.  National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.

Authors:  Mark Olfson; Carlos Blanco; Linxu Liu; Carmen Moreno; Gonzalo Laje
Journal:  Arch Gen Psychiatry       Date:  2006-06

2.  Rating scales, scales of measurement, issues of reliability: resolving some critical issues for clinicians and researchers.

Authors:  Domenic Cicchetti; Richard Bronen; Susan Spencer; Sheryl Haut; Anne Berg; Patricia Oliver; Peter Tyrer
Journal:  J Nerv Ment Dis       Date:  2006-08       Impact factor: 2.254

3.  Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data.

Authors:  J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-07       Impact factor: 8.829

4.  Diagnoses and antipsychotic treatment among youths in a public mental health system.

Authors:  Nick C Patel; M Lynn Crismon; Alan Shafer
Journal:  Ann Pharmacother       Date:  2006-01-24       Impact factor: 3.154

5.  Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004.

Authors:  Rajender R Aparasu; Vinod Bhatara
Journal:  Curr Med Res Opin       Date:  2007-01       Impact factor: 2.580

6.  Trends in prescribing of antipsychotic medications for US children.

Authors:  William O Cooper; Patrick G Arbogast; Hua Ding; Gerald B Hickson; D Catherine Fuchs; Wayne A Ray
Journal:  Ambul Pediatr       Date:  2006 Mar-Apr

7.  Phenomenology of children and adolescents with bipolar spectrum disorders.

Authors:  David Axelson; Boris Birmaher; Michael Strober; Mary Kay Gill; Sylvia Valeri; Laurel Chiappetta; Neal Ryan; Henrietta Leonard; Jeffrey Hunt; Satish Iyengar; Jeffrey Bridge; Martin Keller
Journal:  Arch Gen Psychiatry       Date:  2006-10

8.  Preliminary studies of the reliability and validity of the children's depression rating scale.

Authors:  E O Poznanski; J A Grossman; Y Buchsbaum; M Banegas; L Freeman; R Gibbons
Journal:  J Am Acad Child Psychiatry       Date:  1984-03

9.  National trends in the outpatient diagnosis and treatment of bipolar disorder in youth.

Authors:  Carmen Moreno; Gonzalo Laje; Carlos Blanco; Huiping Jiang; Andrew B Schmidt; Mark Olfson
Journal:  Arch Gen Psychiatry       Date:  2007-09

Review 10.  Pediatric bipolar disorder: validity, phenomenology, and recommendations for diagnosis.

Authors:  Eric A Youngstrom; Boris Birmaher; Robert L Findling
Journal:  Bipolar Disord       Date:  2008-02       Impact factor: 6.744

View more
  4 in total

1.  Medical Conditions and Demographic, Service and Clinical Factors Associated with Atypical Antipsychotic Medication Use Among Children with An Autism Spectrum Disorder.

Authors:  Johanna K Lake; Danica Denton; Yona Lunsky; Amy M Shui; Jeremy Veenstra-VanderWeele; Evdokia Anagnostou
Journal:  J Autism Dev Disord       Date:  2017-05

2.  The 24-month course of manic symptoms in children.

Authors:  Robert L Findling; Booil Jo; Thomas W Frazier; Eric A Youngstrom; Christine A Demeter; Mary A Fristad; Boris Birmaher; Robert A Kowatch; Eugene Arnold; David A Axelson; Neal Ryan; Jessica C Hauser; Daniel J Brace; Linda E Marsh; Mary Kay Gill; Judith Depew; Brieana M Rowles; Sarah McCue Horwitz
Journal:  Bipolar Disord       Date:  2013-06-26       Impact factor: 6.744

3.  Pediatric psychopharmacology: too much or too little?

Authors:  Judith L Rapoport
Journal:  World Psychiatry       Date:  2013-06       Impact factor: 49.548

4.  The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children.

Authors:  Meredith Matone; Russell Localio; Yuan-Shung Huang; Susan dosReis; Chris Feudtner; David Rubin
Journal:  Health Serv Res       Date:  2012-09-04       Impact factor: 3.402

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.